Use of nasal continuous positive airway pressure as treatment of XXXX .

@entity1 @entity2122 @entity28 @entity27 @entity2507 @entity25
OBJECTIVE: To determine the safety and efficacy of nasal continuous positive airway pressure (CPAP) for @entity27 ( @entity27 ) during childhood and the effects of growth and maturation on CPAP requirements. DESIGN: Retrospective study with use of a written questionnaire administered to pediatric practitioners treating @entity25 . SETTING: Nine academic pediatric @entity25 centers. RESULTS: Data were obtained for 94 @entity1 . Three percent of @entity1 receiving CPAP were less than 1 year, 29% were 1 to 5 years, 36% were 6 to 12 years, and 32% were 13 to 19 years of age; 64% were @entity1 . The longest duration of CPAP use was 4 years. Indications for CPAP included @entity27 associated with @entity28 (27%), @entity2122 (25%), idiopathic @entity27 persisting after adenoidectomy and tonsillectomy (17%), and trisomy 21 (13%). Continuous positive airway pressure was effective in 81 @entity1 (86%), in one @entity1 it was unsuccessful, and in 12 @entity1 compliance was inadequate. The median pressure required was 8 cm @entity2507 (range, 4 to 20 cm @entity2507 ); pressure requirements were independent of age or diagnosis. Twenty-two percent of @entity1 eventually required a modification of CPAP levels. Complications of CPAP were minor. Sixty-four percent of centers reported difficulty in obtaining funding for CPAP. CONCLUSIONS: Continuous positive airway pressure is safe, effective, and well tolerated by @entity1 and adolescents with @entity27 . Experience in @entity1 is limited. As pressure requirements change with @entity1 growth, we recommend that CPAP requirements be regularly reevaluated over time. The marked center-to-center variability in CPAP use suggests that specific indications for this therapy require clarification.
